MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia — Stella

Home/Recurrent Acute Myeloid Leukemia/

View on ClinicalTrials.gov

Recruiting

Back to Recurrent Acute Myeloid Leukemia trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

City of Hope Medical Center, Duarte, California

Key details

Phase

Early testing

Sponsor

City of Hope Medical Center

Collaborators

National Cancer Institute (NCI)

Enrollment target

~12 participants

Started

October 2025

Primary completion

April 2027

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.